Last reviewed 2026-04-22 · How we verify

Crossover iNO

Crossover iNO is an inhaled nitric oxide delivery system that increases nitric oxide levels in the lungs to improve oxygenation and reduce pulmonary vascular resistance.

Crossover iNO is an inhaled nitric oxide delivery system that increases nitric oxide levels in the lungs to improve oxygenation and reduce pulmonary vascular resistance. Used for Acute respiratory distress syndrome (ARDS), Pulmonary hypertension in critically ill patients, Hypoxemic respiratory failure.

At a glance

Mechanism of action

Nitric oxide is a potent pulmonary vasodilator that selectively reduces pulmonary artery pressure and improves ventilation-perfusion matching in the lungs. By delivering iNO via inhalation, the drug acts locally on pulmonary vasculature to improve gas exchange and oxygen delivery while minimizing systemic effects. This mechanism is particularly useful in conditions characterized by pulmonary hypertension and hypoxemia.

Approved indications

• Acute respiratory distress syndrome (ARDS)
• Pulmonary hypertension in critically ill patients
• Hypoxemic respiratory failure

Common side effects

• Methemoglobinemia
• Nitrogen dioxide exposure
• Rebound pulmonary hypertension upon discontinuation

Key clinical trials

• Inosine Energy Expenditure Study (NA)
• Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure (PHASE4)
• A Food-Drug Interaction Study of Serum Urate After Oral Inosine (PHASE1)
• High-Frequency Oscillatory Ventilation Associated With Inhaled Nitric Oxide in Children (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.